Is the Tail Wagging the Dog in Drug Market Entry?

Posted by Ben Hohn on Wed, Jan 29, 2020

Judith Kulich co-wrote this article with Ben Hohn.

The commercial pharmaceutical market of the 1990s has all but disappeared: Low-priced drugs designed to treat large-market diseases like depression and high cholesterol are making way for higher-priced specialty drugs designed to treat small, targeted patient populations. With this shift, emerging biopharmaceutical companies are not only developing an increasing number of novel drugs, but increasingly launching those assets.


>
Read More

How Biosimilars Follow Their Own Sales Path, in Three Case Studies

Posted by Judith Kulich on Tue, Jan 27, 2015

Here’s a problem that pharma and biotech executives (and we at ZS) are trying hard to solve: When it comes to biosimilars—the biotech drugs rated equivalent to biologic innovators—what will convince physicians, patients and payers to switch?


>
Read More